Wockhardt is in talks with a clutch of multinationals to license its nutrition brand after a bid to sell the nutrition business outright met with opposition from unsecured lenders last year. The company is looking to license its leading nutrition brand, Protinex, for around 400 crore.
According to research agency IMS Health, Protinex is the market leader in the protein-supplement segment with estimated revenues of 100 crore. Wockhardt had bought the brand in 2006 from Dutch company Royal Numico for 60 crore. Wockhardt's nutrition business is estimated to be over 600 crore. Apart from Protinex, the nutrition business also has brands such as Farex, Dexolac and Nusobee.
Earlier in 2010, Wockhardt had initiated talks with Abbott to sell its nutrition business for 3,400 crore. But the deal was called off due to opposition from bondholders. Wockhardt owes over $74 million (around 330 crore) to its bondholders, including Singapore hedge fund QVT and Mumbai's Sun Pharma.crackcrack
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |